Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated. A report into recurrent prostate cancer by Figg et al.1 shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy.
- Eleni Efstathiou
- Christopher J. Logothetis